This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Mental Health Service Line, VA Atlanta Healthcare System, Decatur, Georgia
  2. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia
  3. Corresponding author: Sheila A. M. Rauch, PhD, Emory University School of Medicine, 12 Executive Park, 3rd Floor, Atlanta, GA 30329 ([email protected]).
  4. Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, Michigan
  5. Tonix Pharmaceuticals Inc, New York, New York
  6. Tonix Pharmaceuticals Inc, New York, New York
  7. Mental Health Service Line, Ralph H. Johnson VA Medical Center, Charleston, South Carolina
  8. Department of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Sciences, Houston, Texas
  9. Department of Human Services, University of Virginia, Charlottesville, Virginia
  10. Department of Psychiatry, New York University Grossman School of Medicine, New York, New York
  11. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  12. National Center for PTSD, VA Palo Alto Medical Center, Menlo Park, California
  13. Research Service Line, VA Ann Arbor Healthcare System, Ann Arbor, Michigan
  14. National Center for PTSD, White River Junction VA Medical Center, White River Junction, Vermont
  15. Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, California
  16. VA Center of Excellence for Stress and Mental Health, San Diego, California
  17. PhD Program, California School of Professional Psychology, Alliant International University, San Diego, California
  18. Research Service, VA San Diego Healthcare System, San Diego, California
  19. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan
  20. Mental Health Service Line, VA Ann Arbor Healthcare System, Ann Arbor, Michigan
  21. Mental Health Care Line, VA San Diego Healthcare System, San Diego, California
  22. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  23. Department of Psychiatry, University of Caen Normandy & Caen University Hospital, Caen, France
  24. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
  25. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
  1. VA/DOD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. US Department of Veterans Affairs. 2017. https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf
  2. Clinical Practice Guideline for the Treatment of PTSD. American Psychological Association. 2017. https://www.apa.org/ptsd-guideline/ptsd.pdf
  3. Foa EB, Rothbaum AO, Hembree EA, et al. In: Barlow DH, ed. Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences. 2nd ed. New York, NY: Oxford University Press; 2019.
  4. Lee DJ, Schnitzlein CW, Wolf JP, et al. Psychotherapy versus pharmacotherapy for PTSD: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33:792–806. PubMed CrossRef
  5. Rauch SAM, Kim HM, Powell C, et al. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2019;76(2):117–126. PubMed CrossRef
  6. McFarlane AC, Lawrence-Wood E, Van Hooff M, et al. The need to take a staging approach to the biological mechanisms of PTSD and its treatment. Curr Psychiatry Rep. 2017;19(2):10. PubMed CrossRef
  7. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048–1060. PubMed CrossRef
  8. Armenta RF, Rush T, LeardMann CA, et al; Millennium Cohort Study team. Factors associated with persistent posttraumatic stress disorder among US military service members and veterans. BMC Psychiatry. 2018;18(1):48. PubMed CrossRef
  9. Chard KM, Schumm JA, Owens GP, et al. A comparison of OEF and OIF veterans and Vietnam veterans receiving cognitive processing therapy. J Trauma Stress. 2010;23(1):25–32. PubMed CrossRef
  10. Galovski TE, Blain LM, Mott JM, et al. Manualized therapy for PTSD: flexing the structure of cognitive processing therapy. J Consult Clin Psychol. 2012;80(6):968–981. PubMed CrossRef
  11. Powers MB, Halpern JM, Ferenschak MP, et al. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010;30(6):635–641. PubMed CrossRef
  12. Richardson JD, Elhai JD, Sarreen J. Predictors of treatment response in Canadian combat and peacekeeping veterans with military-related posttraumatic stress disorder. J Nerv Ment Dis. 2011;199(9):639–645. PubMed CrossRef
  13. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(11):860–868. PubMed CrossRef
  14. Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68(5):711–720. PubMed CrossRef
  15. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(12):1974–1981. PubMed CrossRef
  16. Sripada RK, Blow FC, Rauch SAM, et al. Examining the nonresponse phenomenon: Factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. J Anxiety Disord. 2019;63:18–25. PubMed CrossRef
  17. Bartoszek G, Hannan SM, Kamm J, et al. Trauma-related pain, reexperiencing symptoms, and treatment of posttraumatic stress disorder: a longitudinal study of veterans. J Trauma Stress. 2017;30(3):288–295. PubMed CrossRef
  18. Nordin L, Perrin S. Pain and posttraumatic stress disorder in refugees who survived torture: the role of pain catastrophizing and trauma-related beliefs. Eur J Pain. 2019;23(8):1497–1506. PubMed CrossRef
  19. Back SE, Brady KT, Sonne SC, et al. Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis. 2006;194(9):690–696. PubMed CrossRef
  20. Bedard-Gilligan M, Garcia N, Zoellner LA, et al. Alcohol, cannabis, and other drug use: engagement and outcome in PTSD treatment. Psychol Addict Behav. 2018;32(3):277–288. PubMed CrossRef
  21. van Minnen A, Harned MS, Zoellner L, et al. Examining potential contraindications for prolonged exposure therapy for PTSD. Eur J Psychotraumatol. 2012;3(1):3. PubMed CrossRef
  22. van Minnen A, Arntz A, Keijsers GP. Prolonged exposure in patients with chronic PTSD: predictors of treatment outcome and dropout. Behav Res Ther. 2002;40(4):439–457. PubMed CrossRef
  23. Belleau EL, Chin EG, Wanklyn SG, et al. Pre-treatment predictors of dropout from prolonged exposure therapy in patients with chronic posttraumatic stress disorder and comorbid substance use disorders. Behav Res Ther. 2017;91:43–50. PubMed CrossRef
  24. Phelps AJ, Steele Z, Cowlishaw S, et al. Treatment outcomes for military veterans with posttraumatic stress disorder: response trajectories by symptom cluster. J Trauma Stress. 2018;31(3):401–409. PubMed CrossRef
  25. Haagen JFG, Ter Heide FJJ, Mooren TM, et al. Predicting post-traumatic stress disorder treatment response in refugees: multilevel analysis. Br J Clin Psychol. 2017;56(1):69–83. PubMed CrossRef
  26. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63(3):199–206. PubMed CrossRef
  27. Eftekhari A, Crowley JJ, Mackintosh M-A, et al. Predicting treatment dropout among veterans receiving prolonged exposure therapy. Psychol Trauma. 2020;12(4):405–412. PubMed CrossRef
  28. McClendon J, Dean KE, Galovski T. Addressing diversity in PTSD treatment: disparities in treatment engagement and outcome among patients of color. Curr Treat Options Psychiatry. 2020;7(3):275–290. CrossRef
  29. Jaycox LH, Foa EB, Morral AR. Influence of emotional engagement and habituation on exposure therapy for PTSD. J Consult Clin Psychol. 1998;66(1):185–192. PubMed CrossRef
  30. Marks I, Lovell K, Noshirvani H, et al. Treatment of posttraumatic stress disorder by exposure and/or cognitive restructuring: a controlled study. Arch Gen Psychiatry. 1998;55(4):317–325. PubMed CrossRef
  31. Rauch SAM, Simon NM, Kim HM, et al. Integrating biological treatment mechanisms into randomized clinical trials: design of PROGrESS (PROlonGed ExpoSure and Sertraline Trial). Contemp Clin Trials. 2018;64:128–138. PubMed CrossRef
  32. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
  33. Blake DD, Weathers FW, Nagy LM, et al. The development of a clinician-administered PTSD scale. J Trauma Stress. 1995;8(1):75–90. PubMed CrossRef
  34. Wilkins KC, Lang AJ, Norman SB. Synthesis of the psychometric properties of the PTSD checklist (PCL) military, civilian, and specific versions. Depress Anxiety. 2011;28(7):596–606. PubMed CrossRef
  35. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138. PubMed
  36. de Vroege L, Hoedeman R, Nuyen J, et al. Validation of the PHQ-15 for somatoform disorder in the occupational health care setting. J Occup Rehabil. 2012;22(1):51–58. PubMed CrossRef
  37. Kubany ES, Haynes SN, Abueg FR, et al. Development and validation of the Trauma-Related Guilt Inventory (TRGI). Psychol Assess. 1996;8(4):428–444. CrossRef
  38. Rauch SAM, King A, Kim HM, et al. Cortisol awakening response in PTSD treatment: predictor or mechanism of change. Psychoneuroendocrinology. 2020;118:104714. PubMed CrossRef
  39. Joshi SA, Duval ER, Sheynin J, et al. Neural correlates of emotional reactivity and regulation associated with treatment response in a randomized clinical trial for posttraumatic stress disorder. Psychiatry Res Neuroimaging. 2020;299:111062. PubMed CrossRef
  40. Duval ER, Sheynin J, King AP, et al. Neural function during emotion processing and modulation associated with treatment response in a randomized clinical trial for posttraumatic stress disorder. Depress Anxiety. 2020;37(7):670–681. PubMed CrossRef
  41. Sheynin J, Duval ER, King AP, et al. Associations between resting-state functional connectivity and treatment response in a randomized clinical trial for posttraumatic stress disorder. Depress Anxiety. 2020;37(10):1037–1046. PubMed CrossRef
  42. Joksimovic SL, Covey DF, Jevtovic-Todorovic V, et al. Neurosteroids in pain management: a new perspective on an old player. Front Pharmacol. 2018;9:1127. PubMed CrossRef
  43. Benuto LT, Bennett NM, Casas JB. Minority participation in randomized controlled trials for prolonged exposure therapy: a systematic review of the literature. J Trauma Stress. 2020;33(4):420–431. PubMed CrossRef